(HealthDay News) — Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases compared with sulfonylureas among adults with type 2 diabetes ...
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases ...
A comparative effectiveness study of glucose-lowering drugs finds the GLP-1 receptor agonists most protective against ...
The diabetes drug empagliflozin (Jardiance) and an insulin nasal spray both showed promising effects on memory, brain health ...
A type 2 diabetes medication may lower the risk of autoimmune rheumatic diseases like rheumatoid arthritis by 11%, unlike ...
For patients with diabetes and early-stage pulmonary malignancies, administration of a sodium-glucose cotransporter 2 ...
Novo Nordisk announced its oral GLP-1 has been approved by the FDA to reduce risk for major adverse cardiovascular events in ...
Phenotyping patients can help to identify potential heart failure with preserved ejection fraction (HFpEF) as well as improve patient outcomes.
Real-world data reinforce SGLT2 inhibitors as first-line therapy for frail, older adults with heart failure with preserved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback